More tools:Markets·Screener·Research·Chat

iBio, Inc. Common Stock (IBIO) Financial Statements

iBio, Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001T0R8W3
XNAS · usd
1.30▼ 0.01 (-0.76%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value—
Trailing P/E—
Price / Sales
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt—
Trading Information
Previous Close1.31
Day's Range1.28 – 1.32
52-Week Range0.77 – 3.82
Volume190.3K
Avg Volume644.6K
Share Statistics
Shares Outstanding
Employees20
ExchangeXNAS
Listed2008-08-19
Share count as of August 27, 2026
Loading Income Statement…
Key questions about iBio, Inc. Common Stock (IBIO)
What is iBio, Inc. Common Stock's Market Cap?
iBio, Inc. Common Stock's Market Cap is $83.6M, based on as-reported figures from SEC (XBRL) filings.
What is iBio, Inc. Common Stock's Price / Sales?
iBio, Inc. Common Stock's Price / Sales is 836.0×, based on as-reported figures from SEC (XBRL) filings.
What is iBio, Inc. Common Stock's Revenue (TTM)?
iBio, Inc. Common Stock's Revenue (TTM) is $100.0K, based on as-reported figures from SEC (XBRL) filings.
What is iBio, Inc. Common Stock's Net Income (TTM)?
iBio, Inc. Common Stock's Net Income (TTM) is -$33.0M, based on as-reported figures from SEC (XBRL) filings.
What is iBio, Inc. Common Stock's EBITDA?
iBio, Inc. Common Stock's EBITDA is -$34.6M, based on as-reported figures from SEC (XBRL) filings.
What is iBio, Inc. Common Stock's Diluted EPS (TTM)?
iBio, Inc. Common Stock's Diluted EPS (TTM) is -0.51, based on as-reported figures from SEC (XBRL) filings.
What is iBio, Inc. Common Stock's EBITDA Margin?
iBio, Inc. Common Stock's EBITDA Margin is -34563.0%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Consolidated Statements of Operations
Revenue
YoY growth-100.0%—-100.0%—
Operating expenses:
Research and development
General and administrative
Total operating expenses
% of revenue———6051.0%
Operating loss
% of revenue———-5951.0%
Other income (expense):
Interest income
Interest expense
Total other income
Net loss
% of revenue———-5720.0%
Loss per common share - basic
Loss per common share - diluted